Annual Conference & Webinar Schedule

Please join Acella Pharmaceuticals for the following conferences and register to attend one of our product theaters highlighting NP Thyroid®.


Nurse Practitioner Associates for Continuing Education

February 27 - March 2 – Savannah, GA


Nurse Practitioner Associates for Continuing Education

April 29-26 – Denver, CO


American Academy of Physician Associates

May 20-27 – Nashville, TN

Booth #: 1115


Endocrine Society

June 15-18 – Chicago, IL

Booth #: 1844

Product Theater

Thursday, June 15 at 12:30-1:30 pm CT
with Speakers Thanh Hoang, DO, FACP, FACE, Elizabeth McAninch, MD, and David Robertson, MD


Treating Hypothyroidism: A Contemporary Clinical Perspective on DTE and its Value for Patient Care

American Association of Nurse Practitioners

June 20-25 – New Orleans, LA

Booth #: 419

Product Theater

Wednesday, June 21 at 12:15-1:15 pm CT
with Speakers Angela Golden, DNP, FNP-C, FAANP and Christine Kessler, MN, ANP-BC, CNS, BC-ADM, FAANP


When Hypothyroid Patients Speak, Are We Listening? An Expert Discussion on Patient Preference and Satisfaction

Live Educational Webinar

June 27

Live Webcast

Tuesday, June 27 at 12:00 pm, 1:00 pm, and 3:00 pm ET
with Speaker Angela Mazza, DO, ABAARM, FAAMFM, ECNU, CDE


Hypothyroidism Uncovered Educational Series Presents: Reconsidering Treatment from a Patient-Focused Perspective

Nurse Practitioner Associates for Continuing Education

June 28-30 – Boston, MA

Booth #: TBD


National Nurse Practitioner Symposium

July 20-23 – Keystone, CO

Booth #: 109

Product Theater

Thursday, July 20 at 11:30 am-1:00 pm MT
with Speaker Christine Kessler, MN, ANP-BC, CNS, BC-ADM, FAANP


When Hypothyroid Patients Speak, Are We Listening? Patient-focused Approaches, New Scientific Insights


Florida Nurse Practitioner Network

August 24-26 – Orlando, FL

Booth #: TBD

Product Theater

Friday, August 25 at 12:40-1:40 pm ET
with Speaker Carolyn Zaumeyer, MSN, APRN


When Hypothyroid Patients Speak, Are We Listening? A Patient-Focused Approach to Managing Persistent Symptoms

Western Endocrine Association

Aug 25-27 – Sedona, AZ

Booth #: TBD


American Thyroid Association

September 27 - October 1 – Washington, DC

Booth #: 306

Product Theater

Thursday, September 28 at 11:45 am-12:45 pm
with Speakers Thanh D. Hoang, DO, FACP, FACE and Elizabeth A. McAninch, MD


Changing the Paradigm of Hypothyroidism Treatment: Two Researchers’ Perspectives

North American Menopause Society

September 27-30 – Philadelphia, PA

Booth #: TBD

Texas Nurse Practitioner Conference

September 28 - October 1 – Dallas, TX

Booth #: TBD

Product Theater

Friday, September 29 at 12:15-1:15 pm CT
with Speaker Mandy Cotten, APRN, FNP-C


When Hypothyroid Patients Speak, Are We Listening? Patient-focused Approaches, New Scientific Insights



October 12–14 – Orlando, FL

Booth #: TBD

Family Medicine Experience

October 26-30 – Chicago, IL

Booth #: TBD

Nurse Practitioners in Women's Health

October 29 - November 1 – San Diego, CA

Booth #: TBD

Product Theater

Monday, October 30 at 5:30-7:00 pm PT
with Speakers Christine Kessler, MN, ANP-BC, CNS, BC-ADM, FAANP and Barbara Dehn, NP


Coming Soon


American Academy of Anti-Aging Medicine

December 14-16 – Las Vegas, NV

Booth #: 7099

Important Risk Information

Drugs with thyroid hormone activity, alone or together with other therapeutic agents, have been used for the treatment of obesity. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life-threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects.
  • NP Thyroid® is contraindicated in patients with uncorrected adrenal insufficiency, untreated thyrotoxicosis, and hypersensitivity to any component of the product.
  • In the elderly and in patients with cardiovascular disease, NP Thyroid® should be used with greater caution than younger patients or those without cardiovascular disease.
  • Use of NP Thyroid® in patients with diabetes mellitus or adrenal cortical insufficiency may worsen the intensity of their symptoms.
  • The therapy of myxedema coma requires simultaneous administration of glucocorticoids.
  • Concomitant use of NP Thyroid® with oral anticoagulants alters the sensitivity of oral anticoagulants. Prothrombin time should be closely monitored in thyroid-treated patients on oral anticoagulants.
  • In infants, excessive doses of NP Thyroid® may produce craniosynostosis.
  • Partial loss of hair may be experienced by children in the first few months of therapy but is usually transient.
  • Adverse reactions associated with NP Thyroid® therapy are primarily those of hyperthyroidism due to therapeutic overdosage.
  • Many drugs and some laboratory tests may alter the therapeutic response to NP Thyroid®. In addition, thyroid hormones and thyroid status have varied effects on the pharmacokinetics and actions of other drugs. Administer at least 4 hours before or after drugs that are known to interfere with absorption. Evaluate the need for dose adjustments when regularly administering within one hour of certain foods that may affect absorption.
  • NP Thyroid® should not be discontinued during pregnancy, and hypothyroidism diagnosed during pregnancy should be promptly treated.


NP Thyroid® (thyroid tablets, USP) is a prescription medicine that is used to treat a condition called hypothyroidism from any cause, except for cases of temporary hypothyroidism, which is usually associated with an inflammation of the thyroid (thyroiditis). It is meant to replace or supplement a hormone that is usually made by your thyroid gland.

NP Thyroid® is also used in the treatment and prevention of normal functioning thyroid goiters, such as thyroid nodules, Hashimoto’s thyroiditis, multinodular goiter, and in the management of thyroid cancer.